

India's Intas Pharma emerges as largest global supplier of Pegfilgrastim with acquisition of UDENYCA

August 7, 2025 | News

To further expand specialty division across key international markets



India-based Intas Pharmaceuticals, in collaboration with its global subsidiaries operating under the Accord brand, has solidified its position as one of the world's leading suppliers of pegfilgrastim following the successful acquisition of UDENYCA® (pegfilgrastim-cbqv) from Coherus BioSciences, Inc.

UDENYCA, a biosimilar to Neulasta® (pegfilgrastim), significantly expands Intas and Accord's FDA-approved biosimilar portfolio and accelerates their strategic growth in the global biosimilar market.

Accord is already a pegfilgrastim market leader in Europe—having been the first to commercialise a biosimilar pegfilgrastim and the only company to launch an autoinjector—has maintained its leadership despite intense competition. This acquisition further strengthens the company's presence and impact in both the US and international biosimilar landscapes.

With the acquisition, Accord BioPharma, the US specialty business of Intas, continues the commercialization of UDENYCA to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

UDENYCA offers three patient-friendly administration options—autoinjector (AI), on-body injector (OBI), and prefilled syringe (PFS)—providing flexibility for treatment at home, on-the-go, or in clinical settings. Since its commercial launch, over 300,000 patients have been treated with UDENYCA and more than 1.4 million units have been distributed.

The acquisition not only expands Accord BioPharma's product offerings but also brings a wealth of talent from Coherus BioSciences. Key Coherus employees across multiple functions, including Sales, Marketing, Finance, Supply Chain, and Quality and Manufacturing, who have joined Accord BioPharma, will play a crucial role in supply and services continuity/transition and expanding the company's work around UDENYCA.